Here, we reported that the HIMS condition resets CD4+ T cells programming and redirects the immune response by increasing expression of IL-4, RAR-α, AHR, LXR-α and MERTK along with decreased SGK1, IL-22, and IL-17 when compared with the MS cohort. The gene discussed is IL17A; the disease is myeloid sarcoma.